oxycodone

(redirected from Oxecta)
Also found in: Dictionary.

oxycodone

 [ok″se-ko´dōn]
an opioid analgesic derived from morphine; used in the form of the hydrochloride and terephthalate salts, administered orally or rectally.

ox·y·co·done

(ok'sē-kō'dōn),
A narcotic analgesic often prepared with aspirin or acetaminophen.

oxycodone

(ŏk′sĭ-kō′dōn′)
n.
A semisynthetic opioid drug, C18H21NO4, used in its hydrochloride form as a pain reliever, often in combination with nonopioid analgesics such as acetaminophen.

oxycodone

Hillbilly heroin, poor man's heroin, redneck heroin Pharmacology An oral opioid analgesic, which may be coadministered with other analgesics Pharmacologic effects Morphine-like actions; blocks CNS responses to pain; CNS depressant; analgesic. See Opioids, OxyContin.

ox·y·co·done

(ok'sē-kō'dōn)
A narcotic analgesic often prepared with aspirin or acetaminophen.
References in periodicals archive ?
Specialty pharmaceutical company Acura Pharmaceuticals Inc (Nasdaq: ACUR) announced on Monday the expansion of commercialisation of OXECTA (oxycodone HCl) Tablets CII by Pfizer Inc (NYSE: PFE) to health care providers in US in the fourth quarter of 2013.
Acura has exclusively licensed its AVERSION technology to Pfizer in the US, Canada and Mexico for use in OXECTA. Acura receives tiered royalties ranging from 5% to 25% on net sales of OXECTA.
OXECTA is covered by US patents issued to Acura and licensed to Pfizer Inc (NYSE:PFE).
24 January 2012 - Acura Pharmaceuticals, Inc (NASDAQ:ACUR) said on Monday it had received information from Pfizer Inc (NYSE:PFE) on the commercial availability of OXECTA (oxycodone HCl, USP) Tablets CII.
OXECTA is indicated to manage acute and chronic moderate to severe pain where the use of an opioid analgesic is appropriate.
OXECTA, which utilises Acura's AVERSION Technology, will be sold in bottles of 100 tablets in 5mg and 7.5mg dosage strengths.
M2 PHARMA-October 17, 2011-Pfizer to start commercialisation of OXECTA in US(C)2011 M2 COMMUNICATIONS
M2 EQUITYBITES-July 4, 2011-Acura Pharmaceuticals Inc awarded USD20m milestone payment for FDA's approval of Pfizer Inc's OXECTA used against tampering associated with opioid abuse(C)2011 M2 COMMUNICATIONS http://www.m2.com